PUBLIC COMPANY
saveGC Biopharma Corp
updated 4mo ago
community read0 votes
pipeline
3
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
1Phase 11Phase 21Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA)
- phase3A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years
- phase3An Extension Study to Assess the Long-term Safety and Efficacy of Hunterase (Idursulfase Beta)
- phase1A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient
- phase2A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease
- phase3Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency
- —Evaluation of the Effectiveness and Safety of Rozetel Tablet in Patients After PCI: A Multi-Center Observational Study
- phase2A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults
🐶 Hiring Signal
News
- Osivax bags flu vaccine rights to pursue combination shot visionOsivax has licensed an influenza vaccine from GC Biopharma, positioning the biotech to build on early evidence that its midphase candidate complements traditional flu shots.fiercebiotech · 1mo ago
comments(0)
5-min edit window · permanent after that